| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2013 | WO2013067284A1 Methods of improving or preserving lung function in a patient with a pulmonary disorder |
| 05/10/2013 | WO2013067277A1 Alkylated piperazine compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067274A1 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067267A1 Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
| 05/10/2013 | WO2013067264A1 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| 05/10/2013 | WO2013067260A1 Bicyclic piperazine compounds |
| 05/10/2013 | WO2013067248A1 Benzoxazines as modulators of ion channels |
| 05/10/2013 | WO2013067195A1 Methods and compositions for wound treatment |
| 05/10/2013 | WO2013067165A1 Combination therapy of hsp90 inhibitors with platinum-containing agents |
| 05/10/2013 | WO2013067163A1 Neprilysin inhibitors |
| 05/10/2013 | WO2013067162A1 Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| 05/10/2013 | WO2013067157A1 Compositions and methods for reduction of amyloid-beta load |
| 05/10/2013 | WO2013067154A1 Compositions and methods for hemostasis |
| 05/10/2013 | WO2013067150A2 Composition with sustained antimicrobial activity |
| 05/10/2013 | WO2013067147A1 A composition and method of delivery of l-arabinose and select compounds |
| 05/10/2013 | WO2013067146A1 Methods and compositions for modulating gastrointestinal bacteria to promote health |
| 05/10/2013 | WO2013067142A1 Compounds and treatment methods |
| 05/10/2013 | WO2013067141A1 N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies |
| 05/10/2013 | WO2013067125A1 Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
| 05/10/2013 | WO2013067084A1 Silylated azulenyl nitrone spin traps as chromotropic superoxide detectors |
| 05/10/2013 | WO2013067076A2 Methods and compositions for neuroprotection |
| 05/10/2013 | WO2013067043A1 Methods for treating cancers using oral formulations of cytidine analogs |
| 05/10/2013 | WO2013067040A1 Methods and compositions for treatment of autism |
| 05/10/2013 | WO2013067036A1 Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| 05/10/2013 | WO2013066903A1 Combinational liposome compositions for cancer therapy |
| 05/10/2013 | WO2013066869A1 Piperidinyl-substituted lactams as gpr119 modulators |
| 05/10/2013 | WO2013066864A1 Combination anti-cancer therapy |
| 05/10/2013 | WO2013066839A2 Compounds and methods |
| 05/10/2013 | WO2013066838A1 Compounds and methods |
| 05/10/2013 | WO2013066835A2 Compounds and methods |
| 05/10/2013 | WO2013066834A1 Compounds and methods |
| 05/10/2013 | WO2013066833A1 Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| 05/10/2013 | WO2013066832A1 Compounds and methods |
| 05/10/2013 | WO2013066753A1 Compositions useful for the treatment of viral diseases |
| 05/10/2013 | WO2013066748A1 Methods and compositions for treating hepatitis c virus |
| 05/10/2013 | WO2013066721A2 Methods and compositions for the specific inhibition of met by double-stranded rna |
| 05/10/2013 | WO2013066718A2 Inhibitors of the renal outer medullary potassium channel |
| 05/10/2013 | WO2013066684A1 Aminopyrimidine kinase inhibitors |
| 05/10/2013 | WO2013066643A1 Compositions and methods employing wolbachia ftsz as a target for albendazole sulfone |
| 05/10/2013 | WO2013066640A1 Substituted pyrazole analogues as rar antagonists |
| 05/10/2013 | WO2013066623A1 Anti Aging Application and Method for Treating Aging |
| 05/10/2013 | WO2013066483A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 05/10/2013 | WO2013066481A2 Cosmetic use of n-heteroarylbisamide analogs and related compounds |
| 05/10/2013 | WO2013066469A2 Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics |
| 05/10/2013 | WO2013066440A1 Treatment of breast cancer |
| 05/10/2013 | WO2013066375A1 Methods, formulations, and kits for rapidly repleting folate levels in women |
| 05/10/2013 | WO2013066368A1 Use of mirna 126 to produce hematopoietic stem cells |
| 05/10/2013 | WO2013066353A1 Methods for treating gout flares |
| 05/10/2013 | WO2013066352A1 Methods for treating gout in patient subpopulations |
| 05/10/2013 | WO2013066349A1 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
| 05/10/2013 | WO2013066280A1 Water soluble antipsychotic formulations |
| 05/10/2013 | WO2013066279A1 Solid dosage forms comprising ezetimibe |
| 05/10/2013 | WO2013066278A1 A process for production of pharmaceutical formulations comprising nateglinide |
| 05/10/2013 | WO2013066277A1 Synergic compositions |
| 05/10/2013 | WO2013066181A1 Imaging ligands |
| 05/10/2013 | WO2013066179A1 Liposomal corticosteroids for treatment of inflammatory disorders in humans |
| 05/10/2013 | WO2013066168A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | WO2013066167A1 Method for improving executive function |
| 05/10/2013 | WO2013066165A1 Improving recognition |
| 05/10/2013 | WO2013066153A1 Composition for improving neuropsychological test battery score |
| 05/10/2013 | WO2013066152A1 Method for improving executive function |
| 05/10/2013 | WO2013066151A1 Improving recognition |
| 05/10/2013 | WO2013066134A2 Novel cinnamyl-rhodanine derivatives and pharmaceutical composition comprising same as active ingredients |
| 05/10/2013 | WO2013066028A1 Improved-safety entecavir-containing pharmaceutical composition and production method therefor |
| 05/10/2013 | WO2013065936A1 Complex agent containing clopidogrel and aspirin |
| 05/10/2013 | WO2013065922A1 Pharmaceutical composition including a diphenylpropenone compound as an active ingredient for preventing and treating an inflammatory disorder in the nervous system |
| 05/10/2013 | WO2013065913A1 Gene therapy for diabetic neuropathy using an hgf isoform |
| 05/10/2013 | WO2013065866A1 A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent |
| 05/10/2013 | WO2013065835A1 Pharmaceutical composition for treating diabetes |
| 05/10/2013 | WO2013065825A1 Cationic lipid |
| 05/10/2013 | WO2013065791A1 Double-stranded nucleic acid molecule for gene expression control |
| 05/10/2013 | WO2013065725A1 Phthalamide derivative, pesticide for agricultural and horticultural applications which comprises said derivative, and method of utilizing said pesticide |
| 05/10/2013 | WO2013065720A1 Ophthalmological aqueous composition |
| 05/10/2013 | WO2013065719A1 Ophthalmological aqueous composition |
| 05/10/2013 | WO2013065712A1 Diazaspirourea derivative and pharmaceutical use thereof |
| 05/10/2013 | WO2013065690A1 Prophylactic or therapeutic agent for virus infectious disease |
| 05/10/2013 | WO2013065383A1 Novel compound, method for producing same, and use of same |
| 05/10/2013 | WO2013065224A1 Non-alcoholic beverage containing eudesmol |
| 05/10/2013 | WO2013065068A1 Oral disintegrating composition of anti-histamine agents |
| 05/10/2013 | WO2013065065A1 Optically active fluconazole analogues containing thiophenes as antifungal agents |
| 05/10/2013 | WO2013065063A1 Anhydrous form of dasatinib, process for its preparation and its use |
| 05/10/2013 | WO2013065051A1 Formulation and device for treating ceruminosis |
| 05/10/2013 | WO2013065029A1 Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections |
| 05/10/2013 | WO2013065028A1 Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections |
| 05/10/2013 | WO2013064984A1 Biaryl ether sulfonamides and their use as therapeutic agents |
| 05/10/2013 | WO2013064983A1 Benzenesulfonamide compounds and their use as therapeutic agents |
| 05/10/2013 | WO2013064919A1 Quinazoline derivatives with hsp90 inhibitory activity |
| 05/10/2013 | WO2013064900A1 Oral immediate release formulations for substituted quinazolinones |
| 05/10/2013 | WO2013064884A1 Quaternized amines as sodium channel blockers |
| 05/10/2013 | WO2013064883A1 Heteroaryl compounds as sodium channel blockers |
| 05/10/2013 | WO2013064853A1 Reduced dose oral pharmaceutical compositions of fenofibrate |
| 05/10/2013 | WO2013064818A1 Aptamers |
| 05/10/2013 | WO2013064787A1 Quick-acting insulin formulation including an oligosaccharide |
| 05/10/2013 | WO2013064714A1 Drugs for inhibiting p38 and uses thereof |
| 05/10/2013 | WO2013064703A2 Fkbp subtype-specific rapamycin analogue for use in treatment of diseases |
| 05/10/2013 | WO2013064692A1 Triple combination for the treatment of cancer |
| 05/10/2013 | WO2013064681A1 N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use |
| 05/10/2013 | WO2013064672A2 Oxazaphosphorines dosed one time for treating diseases |
| 05/10/2013 | WO2013064620A1 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17β-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis |
| 05/10/2013 | WO2013064594A1 Gold compounds having alkynyl ligands and therapeutic use thereof |